Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.
Identifieur interne : 000050 ( PubMed/Checkpoint ); précédent : 000049; suivant : 000051Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.
Auteurs : Karim Selfani [Canada] ; Valérie L. Soland ; Sylvain Chouinard ; Philippe HuotSource :
- The neurologist [ 2331-2637 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Aged, Akathisia, Drug-Induced (etiology), Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Aripiprazole (administration & dosage), Aripiprazole (adverse effects), Female, Humans, Male, Middle Aged, Parkinson Disease, Secondary (chemically induced), Tardive Dyskinesia (chemically induced), Young Adult.
- MESH :
- chemical , administration & dosage : Antipsychotic Agents, Aripiprazole.
- chemical , adverse effects : Antipsychotic Agents, Aripiprazole.
- chemically induced : Parkinson Disease, Secondary, Tardive Dyskinesia.
- etiology : Akathisia, Drug-Induced.
- Adult, Aged, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise. Here, we seek to report further cases of aripiprazole-induced movement disorders to raise the awareness of clinicians on this adverse effect.
DOI: 10.1097/NRL.0000000000000096
PubMed: 28009769
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28009769Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.</title><author><name sortKey="Selfani, Karim" sort="Selfani, Karim" uniqKey="Selfani K" first="Karim" last="Selfani">Karim Selfani</name><affiliation wicri:level="1"><nlm:affiliation>*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Soland, Valerie L" sort="Soland, Valerie L" uniqKey="Soland V" first="Valérie L" last="Soland">Valérie L. Soland</name></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28009769</idno><idno type="pmid">28009769</idno><idno type="doi">10.1097/NRL.0000000000000096</idno><idno type="wicri:Area/PubMed/Corpus">000107</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000107</idno><idno type="wicri:Area/PubMed/Curation">000107</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000107</idno><idno type="wicri:Area/PubMed/Checkpoint">000107</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000107</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.</title><author><name sortKey="Selfani, Karim" sort="Selfani, Karim" uniqKey="Selfani K" first="Karim" last="Selfani">Karim Selfani</name><affiliation wicri:level="1"><nlm:affiliation>*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Soland, Valerie L" sort="Soland, Valerie L" uniqKey="Soland V" first="Valérie L" last="Soland">Valérie L. Soland</name></author><author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name></author><author><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name></author></analytic><series><title level="j">The neurologist</title><idno type="eISSN">2331-2637</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Akathisia, Drug-Induced (etiology)</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (adverse effects)</term><term>Aripiprazole (administration & dosage)</term><term>Aripiprazole (adverse effects)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Tardive Dyskinesia (chemically induced)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term><term>Aripiprazole</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Aripiprazole</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term><term>Tardive Dyskinesia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Akathisia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise. Here, we seek to report further cases of aripiprazole-induced movement disorders to raise the awareness of clinicians on this adverse effect.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28009769</PMID><DateCreated><Year>2016</Year><Month>12</Month><Day>23</Day></DateCreated><DateCompleted><Year>2017</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2331-2637</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The neurologist</Title><ISOAbbreviation>Neurologist</ISOAbbreviation></Journal><ArticleTitle>Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.</ArticleTitle><Pagination><MedlinePgn>24-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NRL.0000000000000096</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors. Because of its partial agonist activity, it was believed that aripiprazole would be less susceptible than typical antipsychotics to induce extrapyramidal side effects. However, a few case-reports and case-series detailing aripiprazole-induced movement disorders have been published, suggesting that aripiprazole-induced movement disorders may arise. Here, we seek to report further cases of aripiprazole-induced movement disorders to raise the awareness of clinicians on this adverse effect.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients referred to the André-Barbeau Movement Disorder clinic treated with aripiprazole were enrolled in this study. Their charts were retrospectively reviewed and data regarding past psychiatric history, past antipsychotic medication, duration of aripiprazole treatment, daily dose of aripiprazole administered, and resulting movement disorders were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We report 14 cases of parkinsonism, tardive dyskinesia and akathisia induced by aripiprazole. Some of these, mostly the parkinsonian phenotype, abated spontaneously following drug discontinuation, whereas others, mostly related to tardive phenomena, persisted after aripiprazole was discontinued, and required treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This case-series adds to the existing literature that suggests that movement disorders may arise following treatment with aripiprazole. Clinicians should be aware of this potential side effect when prescribing aripiprazole to patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selfani</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>*Unité des Troubles du Mouvement André Barbeau †Division of Neurology, Centre Hospitalier de l'Université de Montréal Departments of ‡Neuroscience §Pharmacology, Université de Montréal ∥Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soland</LastName><ForeName>Valérie L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Chouinard</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Huot</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurologist</MedlineTA><NlmUniqueID>9503763</NlmUniqueID><ISSNLinking>1074-7931</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017109" MajorTopicYN="N">Akathisia, Drug-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071057" MajorTopicYN="N">Tardive Dyskinesia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28009769</ArticleId><ArticleId IdType="doi">10.1097/NRL.0000000000000096</ArticleId><ArticleId IdType="pii">00127893-201701000-00005</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name><name sortKey="Huot, Philippe" sort="Huot, Philippe" uniqKey="Huot P" first="Philippe" last="Huot">Philippe Huot</name><name sortKey="Soland, Valerie L" sort="Soland, Valerie L" uniqKey="Soland V" first="Valérie L" last="Soland">Valérie L. Soland</name></noCountry><country name="Canada"><noRegion><name sortKey="Selfani, Karim" sort="Selfani, Karim" uniqKey="Selfani K" first="Karim" last="Selfani">Karim Selfani</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000050 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28009769
|texte= Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28009769" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |